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Abstract
c-Jun activation domain-binding protein1 (Jab1), also known as a monomer or the fifth
component of the constitutive photomorphogenesis 9 signalosome (Csn5) complex,
regulates cell proliferation, cell-cycle progression, and apoptosis and affects a series of
pathways.  Jab1/Csn5 also promotes  cell  transformation and tumorigenesis,  and its
overexpression in many tumor types suggests it is involved in cancer progression and
closely associated with poor cancer prognosis. Jab1/Csn5 dysregulation contributes to
oncogenesis by deactivating several tumor suppressors. Increasing evidence of the role
of Jab1/Csn5 overexpression in breast and other cancers has spurred interest in Jab1/
Csn5  inhibitors  for  cancer  therapy.  In  this  chapter,  we  summarize  the  evidence
demonstrating the importance of Jab1/Csn5 expression in breast and other cancers and
review recent advances in dissecting the Jab1/Csn5 signaling pathway along with its
potential as a therapeutic target for cancer.
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1. Introduction
c-Jun activation domain-binding protein 1 (Jab1), primarily identified as a c-Jun coactivator [1],
is the fifth member of the constitutive photomorphogenesis 9 signalosome (Csn5) complex.
Specifically,  Jab1/Csn5 is an evolutionarily conserved multifunctional protein involved in
developmental processes in eukaryotic organisms and primarily identified as an inhibitor of
light-dependent  growth and transcription  in  Arabidopsis  [2,  3].  Jab1/Csn5  participates  in
deneddylation of neural precursor cell expressed developmentally downregulated gene 8
(NEDD8), transcription factor specificity, and binding of several key molecules. Increasing
evidence indicates that dysregulation of Jab1/Csn5 activity contributes to tumorigenesis, which
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is functionally inactivating several tumor suppressors and key negative regulatory proteins,
including the cyclin-dependent kinase (CDK) inhibitor p27Kip1 (p27), p53, and SMAD4/7 [4].
Jab1/Csn5 is aberrantly expressed in different tumor types and lines of evidence support that it
is a proto-oncogene. In this chapter, we describe some mechanisms by which Jab1/Csn5 is
involved in cancer progression to provide perspective with the hope that these mechanisms will
lay the foundation for future therapeutic intervention.
2. Structural features of Jab1/Csn5
CSN is a conserved protein complex that typically comprises eight subunits 1/mCSN1–CSN81/m
in descending order according to molecular weight [5]. Six of these subunits contain a protea-
some, constitutive photomorphogenesis 9 signalosome, initiation factor 3 domain or PINT
domain, that serves as a structural scaffold for the assembly of the constitutive photomorpho-
genesis 9 signalosome, and the other two subunits contain an MPR1 and PAD1 N-terminal
(MPN) domain [5, 6]. Although both CSN5 and CSN6 have MPN domains; only the CSN5 MPN
domain contains an embedded Jab1/MPN domain metalloenzyme motif (also named as an MPN
+ motif), which is the catalytic center for CSN isopeptidase activity [5]. Jab1/Csn5 contains 334
amino acids and assembles a nuclear export signal (NES) domain near the p27-binding domain
at the end of the C-terminus [7]. This is a rich blend of leucine nuclear export signal sequences,
which are highly conserved among different species. Through interaction with the NES domain,
CRM1, which exports factors from the nucleus, combines with Jab1/Csn5 via an LMB-sensitive
method and then carries the p27 protein out of the nucleus. When the leucine residues of Jab1/
Csn5 are replaced by alanine residues, the NES can reduce Jab1 and CRM1 interaction, which
impacts LMB-dependent nuclear cytoplasmic output process as well as the degradation of p27
in cells.
The catalytic activity of the CSN complex resides in the deneddylation of the CRLs, that is, the
hydrolysis of the cullin-neural precursor cell expressed developmentally downregulated gene
8 (Nedd8) isopeptide bond. Although CSN-dependent Jab1/Csn5 has isopeptidase activity, it
is intrinsically inactive in other physiologically conditions. Although the Jab1/Csn5 active site
is catalytically competent and compatible with di-isopeptide binding, the Ins-1 segment
obstructs access to its substrate-binding site, and structural rearrangements are necessary for
the Nedd8-binding pocket formation. Detailed study of Jab1/Csn5 by molecular dynamics
discovered the flexibility and plasticity of the Ins-1 segment [8]. These studies resulted in the
identification of a molecular trigger implicated in the active/inactive switch that is sufficient
to impose on Jab1/Csn5 an active isopeptidase state. Additionally, a dynamic monomer-dimer
equilibrium exists both in vitro and in vivo and may be functionally relevant [8].
3. Jab1/Csn5 overexpression in breast cancer and other cancer types
Jab1/Csn5 regulates the transcriptional activity of activator protein 1 (AP-1) and also
modulates cell signal transduction, regulating genetic transcription and the stability of the
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protein [1]. Importantly, Jab1/Csn5, alongside with Myc, was found to act as a master
regulator of a wound gene expression signature in breast cancer cells. This study suggests
that Jab1/CSN5 plays an important role in translating the cell stress response to transcription
of response genes that are involved in proliferation and matrix invasiveness [9]. Aberrant
overexpression of Jab1/Csn5 is implicated to play a role in the pathogenesis of several
types of human malignancies and tends to correlate with poor cancer prognosis. Adler et
al.  [10] provided the first evidence that Jab1/Csn5 isopeptidase activity is essential for
human and murine mammary epithelial transformation and progression. In another study,
Jab1/Csn5 expression was low in or absent from normal breast tissue, but it was aberrantly
expressed in 57% (125 of 220) of node-negative breast tumors and 90% (9 of 10) of
metastatic lesions [11]. Importantly, breast cancer patients with Jab1/Csn5-negative tumors
had neither relapse nor disease progression at a median follow-up time of 70 months [12].
Additionally, Jab1/Csn5 was overexpressed in 33% (11 of 33) of benign ovarian tumors
and 68% (32 of 47) of malignant ovarian tumors and correlated with poor overall survival
of ovarian cancer [13]. Additionally, aberrant expression of Jab1/Csn5 has been positively
associated with hepatitis C virus infection and negatively correlated with hepatitis B virus
infection in hepatocellular carcinoma patients, indicating a possible mechanism that
promotes hepatocarcinogenesis [14]. In a study of non-small cell lung cancer patients,
those with elevated Jab1/Csn5 expression had a poorer overall survival rate (44%) after 5
years than did patients with lower Jab1 expression levels (63%) [15]. Jab1/Csn5 expression
also is closely linked with histological differentiation, clinical stage, and lymph node
metastasis in oral squamous cell carcinoma cases [16]. Patients with oral squamous cell
carcinoma, nasopharyngeal carcinoma, and laryngeal squamous cell carcinomas, as well
as those with thyroid carcinomas and Jab1/Csn5 overexpression, tend to have poor overall
survival, indicating a critical role in cancer progression [16–19]. Furthermore, Jab1/Csn5
plays a role in cancer therapy. In particular, depletion of Jab1/Csn5 enhanced the antitumor
effects of cisplatin and ionizing radiation in NPC cells [20, 21].
Researchers have made substantial  progress in deciphering the critical  role  of  Jab1/Csn5
in diverse cellular  and developmental  processes.  However,  little  is  known about the
underlying regulatory principles that  promote Jab1/CSN5 overexpression in cancer.  Jab1/
Csn5 overexpression may result  from Jab1/Csn5  gene amplification.  The Jab1/Csn5  locus
is located on 8q13.1,  which is always amplified in breast cancer and other cancer patients
[9,  22].  As we described above,  several  other signaling pathways may also contribute to
overexpression of  Jab1/Csn5,  such as  interleukin 6/signal  transducer and activator  of
transcription 3 (Stat  3),  human epidermal growth factor receptor 2 (EGFR) (HER–2)/AKT,
and Bcr/Abl.  For example,  the protein psoriasin (S100A7) enhances Jab1/Csn5 as well  as
activator  protein 1  activity and promotes tumorigenesis  [23].  Moreover,  expression of
Jab1/Csn5 is  related to degradation of  p57 protein [24]  and contributes  to  tumor
recurrence [19].  These findings provided a new opportunity to make Jab1/Csn5 a tumor
target.  Identifying the underlying mechanisms of Jab1/Csn5 in cancer still  requires further
exploration,  but  Jab1/Csn5 has proven to be a  useful  diagnostic  and prognostic  marker
for  cancer.
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4. Jab1/Csn5-associated signaling
A number of studies have demonstrated that Jab1 lies at the intersection of several important
signal transduction pathways that are believed to be important in the progression of breast
cancer (Figure 1). Elucidating the regulatory mechanism of Jab1/Csn5 expression in these
pathways will enhance our understanding of breast tumorigenesis.
Figure 1. Jab1/Csn5 regulatory network in breast cancer cases. Jab1/Csn5 plays an essential role in breast cancer pro-
gression. On the one hand, Jab1/Csn5 activity and expression can be regulated by several typical oncogenic signaling
pathways, such as MIF, phosphoinositide 3-kinase/AKT, interleukin-6/Stat3, HER-2/AKT, and EGFR. On the other
hand, Jab1/Csn5 regulates a myriad of proteins involved in cell proliferation, cell cycle, apoptosis, and DDR.
4.1. Jab1/p27 signaling
Increasingly, studies have demonstrated that Jab1/Csn5 overexpression is negatively associ-
ated with p27 expression and poor prognosis [25] for many human cancers. p27 is a member
of the cell-cycle inhibitor family of proteins, which is a primary driving force for cell-cycle
progression through ubiquitination of G1 cyclins and CDK inhibitors, such as cyclinE-CDK2
and cyclinD1-CDK4 [25]. Eventually, p27 causes cell-cycle arrest during G1 phase and inhibits
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cell proliferation. Jab1/Csn5 directly binds to p27 and mediates its shuttling from the nucleus
to cytoplasm in a CRM1-dependent manner via the NES sequence [7]. Furthermore, research-
ers have observed cytoplasmic translocalization of p27 in human cancers and that it correlates
with poor survival [26]. Many studies have demonstrated that Jab1/Csn5 expression increases
along with p27 nuclear translocation, thereby accelerating p27 degradation via the ubiquitin-
proteasome pathway [27]. Also, depletion of Jab1/Csn5 by small interfering RNA substantially
increases p27 expression, including that of the p27/cyclin E/Cdk2 complex, and nuclear
accumulation of p27 and inhibits the cell-cycle transition from G1 to S phase [27]. In addition,
Jab1/Csn5 may degrade p27 through a Skp2-independent mechanism [28]. Investigators found
that Skp2-mediated degradation of p27 mainly occurred in cells undergoing DNA replication
[29]. Interestingly, evidence suggests that elevated AKT (a protein kinase B) expression leads
to decreased p27 expression in the nucleus. AKT-mediated phosphorylation of p27 at Thr187
is known to inactivate p27 and restrain the translocation of p27 into the nucleus. Subsequently,
degradation of p27 by the ubiquitin-proteasome system is associated with dysregulation of
the cell cycle and promotes tumor formation [30]. Hsu et al. [31] provided the first evidence
that Jab1/Csn5 expression may be regulated by HER-2/neu via the AKT signaling pathway.
Whether Jab1 is directly related to AKT or the underlying mechanism of action between them
is currently unknown.
4.2. HER-2 and EGFR signaling
Jab1/Csn5 is linked with EGFR and HER-2/neu receptor signaling in breast tumorigenesis.
Jab1/Csn5 is a downstream target of HER-2/neu, and Jab1/Csn5 overexpression is correlated
with HER-2/neu in breast cancer [32]. HER-2/neu directly activates Jab1/Csn5 promoter
activity and upregulates Jab1/Csn5 mRNA expression via AKT/β-catenin signaling [31].
Suppression of HER-2/neu by treatment with trastuzumab (Herceptin) decreases Jab1/Csn5
expression in different types of cancer cells [33]. Furthermore, Jab1/Csn5 is a target of EGFR
signaling, and its expression correlates with EGFR expression in estrogen receptor-alpha-
negative breast cancer cell lines. EGFR activation increases the translocation of Jab1/Csn5 to
the nucleus and regulates p27 downstream from Jab1 [34]. These findings suggested that Jab1/
Csn5 is involved in the development and progression of breast cancer.
4.3. Migration inhibitory factor/phosphoinositide 3-kinase/AKT signaling
Jab1/Csn5 controls autocrine macrophage migration inhibitory factor (MIF)-mediated
activation of phosphoinositide 3-kinase/AKT signaling, a novel, indirect mechanism between
the Jab1/Csn5 and phosphoinositide 3-kinase/AKT pathways, by inhibiting MIF secretion and
its autocrine prosurvival activities [35]. In turn, MIF negatively regulates Jab1/Csn5, as MIF
can specifically interact with Jab1/Csn5 and inhibit Jab1/Csn5-enhanced activator protein 1
and c-Jun N-terminal kinase activity [36].
4.4. Interleukin-6/STAT3 signaling
Jab1/Csn5 interacts with protein to regulate unphosphorylated Stat3 DNA-binding activity.
Loss of Jab1/Csn5 expression markedly decreases unphosphorylated Stat3 DNA-binding
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activity as well as expression of Stat3 target genes but tends to increase nuclear Stat3 in
human colon cancer cells [37]. This interesting phenomenon must be studied further to
elucidate how Jab1/Csn5 determines the fate of transcription factors as its binding partners.
Does it do so by binding to target DNA or via protein degradation? In contrast, another study
demonstrated that Stat3 binds to the Jab1/Csn5 promoter, enhances its promoter activity, and
increases Jab1/Csn5 transcription in breast cancer cells. Depletion of Stat3 dramatically
decreases Jab1/Csn5 promoter activity and Jab1/Csn5 mRNA and protein expression [38].
Moreover, upstream activators of Stat3, such as interleukin-6 and Src, also contribute to
activation of Jab1/Csn5 transcription and expression via Stat3.
4.5. Jab1/Csn5 in DNA damage response
In recent years, owing to rapid advances in knowledge of DNA damage repair signal
mechanisms and the study of epigenetic molecular mechanisms, researchers have made
great progress in understanding the principle and mechanism of tumorigenesis after DNA
damage response (DDR). Inactivation of DDR genes increases the risk of accumulating
genetic mutations, which may greatly promote cancer development [4]. Increasing evidence
supports that Jab1/Csn5 affects both the activity and stability of DDR proteins [20]. Jab1/
Csn5 is essential for tumor survival and enhances tumor resistance to chemotherapy and
radiotherapy [20]. Importantly, Jab1/Csn5 can mediate the nuclear export and degradation
of several nuclear proteins, including those involved in DDR [4]. Study results have
demonstrated that Jab1/Csn5 deletion during meiosis can activate the DNA damage
checkpoint in Drosophila melanogaster [39]. CSNs regulate the ubiquitin ligase activity of the
damage DNA-binding protein 1 or DNA-binding protein 2 and Cockayne syndrome group
A complexes in response to exposure to DNA-damaging agents. The authors report that
Jab1/Csn5 deficiency decreased the repair vitality of DNA-binding protein 2 by 50% [40].
Additionally, Cdc10-dependent transcript 1, a licensing factor for the prereplication
complex, is regulated by Jab1/Csn5. Cdc10-dependent transcript 1 is degraded after DNA
damage, and Jab1/Csn5 deficiency may lead to accumulation of Cdc10-dependent transcript
1 [41]. Also, the Rad9/Rad1/Hus1 complex is a DNA damage sensor that transduces DNA
damage and plays an important role in initiation of cellular responses to DNA damage. This
complex promotes ATR-mediated phosphorylation and activation of Chk1, a protein kinase
that regulates progression to S phase, cell-cycle arrest at G2/M, and replication fork
stabilization [42]. Because Jab1/Csn5 is involved in regulating the stability and translocation
of the Rad9/Rad1/Hus1 complex in cells, it likely provides information about Jab1/Csn5 in
checkpoint and DDR [4].
In eukaryotes, Rad51, a key DNA-repair protein, plays a primary role in DNA damage re-
pair using emerging nucleoprotein filaments and mediation of strand conversion among
DNA duplexes [43]. Rad51 is vital for embryo survival in response to exogenous DNA-
damaging stimulation for the repair of spontaneous chromosome breaks during cell devel-
opment [44]. In accordance with these findings, Jab1/Csn5 has been discovered the function
with Rad51 in the homologous recombination repair pathway [43]. Furthermore, Jab1/Csn5
deficiency has not only decreased Rad51 expression but also affected its activity, and the
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absence of Rad51 has caused a large number of chromosome breaks, leading to increased
apoptosis. Decreased Rad51 expression in Jab1/Csn5 knockdown cells is at least partly de-
pendent on p53 expression [20].
5. Predictive and therapeutic roles of Jab1 in cancer cases
Increasingly, studies have demonstrated that overexpressed Jab1/Csn5 is involved in cancer
pathogenesis and correlates with poor cancer prognosis [25]. The authors reported that Jab1+/
p27− patients had poor overall survival of many cancers [13, 25]. Lin Guo’s group recently
provided the first evidence that NCoR is a target of Jab1/Csn5 and mediates endocrine
resistance in breast cancer [45]. Jab1/Csn5 might involve in multiple stages of breast cancer
progression by regulating different protein targets. Further identification and elucidation of
the E3 ligase that connects Jab1/Csn5 and NCoR are of importance to understand the precise
mechanisms underlying endocrine resistance and identify additional druggable molecular
targets. Thus, Jab1/Csn5 is an attractive therapeutic target for cancer given its multiple
prominent functions in many stages of tumorigenesis.
Downregulation of Jab1/Csn5 expression has inhibited growth of and induced apoptosis in
breast cancer [31] and nasopharyngeal carcinoma cells [27]. Furthermore, researchers found
that Jab1/Csn5-deficient mice had an embryonically lethal phenotype, indicating that Jab1/
Csn5 is critical for fetal development and survival [46]. In that study, Jab1/Csn5-null embryos
were smaller than wild-type embryos and displayed delayed growth [46].
Also, the development of Jab1/Csn5-specific inhibitors has had major effects on cancer
treatment. For example, curcumin is a yellow plant pigment that directly inhibits the activity
of Jab1/Csn5-associated kinases, causing cell-cycle arrest in tumor cells during the mitotic
phase and making them more prone to apoptosis by inhibiting Jab1/Csn5 [47]. A recent study
demonstrated that PEGylated curcumin, a water-soluble compound, inhibited the growth of
pancreatic cancer cells and sensitized them to gemcitabine-induced apoptosis [48]. Another
study demonstrated that the curcumin analog T83 markedly induced cell-cycle arrest and
apoptosis in nasopharyngeal carcinoma cells. In addition, T83 effectively inhibited Jab1/Csn5
expression in these cells and sensitized them to radiotherapy [49].
Another potential Jab1/Csn5-targeted drug is troglitazone, a peroxisome proliferator-
activated receptor γ ligand that directly suppresses Jab1/Csn5 promoter activity by inhibit-
ing Sp1- and Tcf4-mediated transcription [32]. A number of in vitro and in vivo studies have
demonstrated that treatment with troglitazone effectively attenuated tumor growth and
upregulated p27 expression in tumor cells in a time- and dose-dependent manner [50].
Animal studies verified that intratumoral or intraperitoneal injection of troglitazone
attenuated hepatocellular carcinoma cell growth and reduced Jab1/Csn5 expression in
hepatocellular tumors [14].
Although increasing evidence demonstrates that Jab1/Csn5 can be used as a therapeutic target
for cancer, much work is still needed to develop a Jab1/Csn5-specific inhibitor for cancer
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treatment. The degree, duration, and cell specificity required for Jab1/Csn5 blockade to
attenuate tumor growth should be studied further.
6. Conclusion and perspective
Jab1/Csn5 is a master regulator of a myriad of protein interactions involved in signaling
pathways, cell survival, apoptosis, and DNA damage repair via ubiquitin-dependent
proteolysis (Figure 1). Although Jab1/Csn5 function has a different role in each tumor type,
overexpressed Jab1/Csn5 is associated with the whole process of carcinogenesis and cancer
progression, and further studies of Jab1/Csn5 as a therapeutic target will provide new insight
into cancer treatment. Considering the pivotal role of Jab1/Csn5 signaling, a reasonable
assumption is that Jab1/Csn5 is a promising diagnostic, prognostic, and therapeutic biomarker
for cancer.
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